Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · REGENXBIO Inc. (RGNX)

REGENXBIO: Director Kenneth Mills resigns from board; George Migausky named chairman

Neutral Impact 2 of 5 leadership Written later

REGENXBIO's board director Kenneth T. Mills resigned effective October 21, 2026, saying he became CEO of another company and will focus on that role, not on any disagreement with the company. The board named George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains on the board. The change is a board governance update with no financial figures disclosed.

Key points

  • Kenneth T. Mills resigned from the board on October 14, 2026, effective October 21, 2026
  • Mr. Mills cited his new role as chief executive officer of another company; filing says no disagreement with the company
  • George Migausky appointed Chairman of the Board
  • Daniel Tassé stepped down as Lead Independent Director under the Corporate Governance Guidelines and remains a director

The filing

CompanyREGENXBIO Inc. (RGNX)
Form8-K, current report
Filed with the SECOct 16, 2026, 7:00 AM ET
Accession number0001193125-26-423376

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.